BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32161058)

  • 21. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
    Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
    Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
    Thein D; Egeberg A; Skov L; Loft N
    JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
    Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
    JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
    Barbulescu A; Delcoigne B; Askling J; Frisell T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
    Paul D; Patil D; McDonald L; Patel V; Lobo F
    J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
    [No Abstract]   [Full Text] [Related]  

  • 29. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
    Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy.
    Genest G; Spitzer KA; Laskin CA
    J Rheumatol; 2018 Aug; 45(8):1109-1115. PubMed ID: 29961692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
    Dreyer L; Magyari M; Laursen B; Cordtz R; Sellebjerg F; Locht H
    Ann Rheum Dis; 2016 Apr; 75(4):785-6. PubMed ID: 26698850
    [No Abstract]   [Full Text] [Related]  

  • 32. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
    Raaschou P; Frisell T; Askling J;
    Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
    Eworuke E; Panucci G; Goulding M; Neuner R; Toh S
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study.
    de Vries MK; Arkema EV; Jonsson J; Bruchfeld J; Jacobsson LTH; Askling J;
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1563-1567. PubMed ID: 29195024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
    Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
    Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
    Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry.
    Lindström Egholm C; Krogh NS; Pincus T; Dreyer L; Ellingsen T; Glintborg B; Kowalski MR; Lorenzen T; Madsen OR; Nordin H; Rasmussen C; Hetland ML
    J Rheumatol; 2015 Oct; 42(10):1781-5. PubMed ID: 26233511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.
    Fong W; Holroyd C; Davidson B; Armstrong R; Harvey N; Dennison E; Cooper C; Edwards CJ
    Rheumatology (Oxford); 2016 Oct; 55(10):1837-42. PubMed ID: 27354684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors.
    Fuchs I; Avnon L; Freud T; Abu-Shakra M
    Clin Rheumatol; 2009 Feb; 28(2):167-72. PubMed ID: 18795393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.